Amyloidosis
IRB #H-26320: Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients with AL Amyloidosis
IRB #H-28441/X50292: Phase II Trial of Induction Therapy with Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation in Patients with AL Amyloidosis
IRB #2011-0284/Millennium #C16007: An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment
IRB #2006-1918/Merck V212: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)
CIRB #H-31166/CTSU #E4A08: A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan, and Dexamethasone (BMDex) for Untreated Patients with Systemic Light-chain (AL) Amyloidosis Ineligible for Autologous Stem-cell
IRB #H-31082/Pomalidomide: A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects with Previously-Treated AL Amyloidosis
